Reporte zur Charge NR5SZ

Symptomtext

Received 3rd dose by error; 1st dose on 19-NOV-2019, 2nd dose 09-NOV-2022; This case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 63-year-old female patient who received Herpes zoster (Shingrix) (batch number NR5SZ, expiry date 22nd October 2022) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 19th November 2019). On 26th May 2021, the patient received the 3rd dose of Shingrix. On 9th November 2020, the patient received the 2nd dose of Shingrix. On 9th November 2020, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 26th May 2021, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered and drug dose administration interval too long were unknown. Additional Information: GSK Receipt Date: 04-MAY-2022 Reporter's Comment: Pharmacist was looking for information if a patient received Shingrix third dose by error. Consented to follow up by email. Additional Supportive Information: The patient received 3rd dose of Shingrix by error, which led to extra dose administered. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.